261 related articles for article (PubMed ID: 33985991)
1. Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial.
Frishberg Y; Deschênes G; Groothoff JW; Hulton SA; Magen D; Harambat J; Van't Hoff WG; Lorch U; Milliner DS; Lieske JC; Haslett P; Garg PP; Vaishnaw AK; Talamudupula S; Lu J; Habtemariam BA; Erbe DV; McGregor TL; Cochat P;
Clin J Am Soc Nephrol; 2021 Jul; 16(7):1025-1036. PubMed ID: 33985991
[TBL] [Abstract][Full Text] [Related]
2. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
Garrelfs SF; Frishberg Y; Hulton SA; Koren MJ; O'Riordan WD; Cochat P; Deschênes G; Shasha-Lavsky H; Saland JM; Van't Hoff WG; Fuster DG; Magen D; Moochhala SH; Schalk G; Simkova E; Groothoff JW; Sas DJ; Meliambro KA; Lu J; Sweetser MT; Garg PP; Vaishnaw AK; Gansner JM; McGregor TL; Lieske JC;
N Engl J Med; 2021 Apr; 384(13):1216-1226. PubMed ID: 33789010
[TBL] [Abstract][Full Text] [Related]
3. Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.
Michael M; Groothoff JW; Shasha-Lavsky H; Lieske JC; Frishberg Y; Simkova E; Sellier-Leclerc AL; Devresse A; Guebre-Egziabher F; Bakkaloglu SA; Mourani C; Saqan R; Singer R; Willey R; Habtemariam B; Gansner JM; Bhan I; McGregor T; Magen D
Am J Kidney Dis; 2023 Feb; 81(2):145-155.e1. PubMed ID: 35843439
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial.
Hayes W; Sas DJ; Magen D; Shasha-Lavsky H; Michael M; Sellier-Leclerc AL; Hogan J; Ngo T; Sweetser MT; Gansner JM; McGregor TL; Frishberg Y
Pediatr Nephrol; 2023 Apr; 38(4):1075-1086. PubMed ID: 35913563
[TBL] [Abstract][Full Text] [Related]
5. Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1.
Hulton SA; Groothoff JW; Frishberg Y; Koren MJ; Overcash JS; Sellier-Leclerc AL; Shasha-Lavsky H; Saland JM; Hayes W; Magen D; Moochhala SH; Coenen M; Simkova E; Garrelfs SF; Sas DJ; Meliambro KA; Ngo T; Sweetser MT; Habtemariam BA; Gansner JM; McGregor TL; Lieske JC
Kidney Int Rep; 2022 Mar; 7(3):494-506. PubMed ID: 35257062
[TBL] [Abstract][Full Text] [Related]
6. Lumasiran: A Review in Primary Hyperoxaluria Type 1.
Kang C
Drugs; 2024 Feb; 84(2):219-226. PubMed ID: 38252335
[TBL] [Abstract][Full Text] [Related]
7. The effect of lumasiran therapy for primary hyperoxaluria type 1 in small infants.
Méaux MN; Sellier-Leclerc AL; Acquaviva-Bourdain C; Harambat J; Allard L; Bacchetta J
Pediatr Nephrol; 2022 Apr; 37(4):907-911. PubMed ID: 35015123
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Sustained Efficacy of Lumasiran at 18 Months in Primary Hyperoxaluria Type 1.
Chiodini B; Tram N; Adams B; Hennaut E; Lolin K; Ismaili K
Front Pediatr; 2021; 9():791616. PubMed ID: 35071135
[No Abstract] [Full Text] [Related]
9. Stiripentol and Lumasiran as a Rescue Therapy for Oxalate Nephropathy Recurrence After Kidney Transplantation in an Adult Patient With Primary Hyperoxaluria Type 1.
Lombardi Y; Isnard P; Chavarot N; Chauvet S; Martinez F; Thervet É; Anglicheau D; Karras A
Am J Kidney Dis; 2023 Jul; 82(1):113-116. PubMed ID: 36693470
[TBL] [Abstract][Full Text] [Related]
10. Improving Treatment Options for Primary Hyperoxaluria.
Hoppe B; Martin-Higueras C
Drugs; 2022 Jul; 82(10):1077-1094. PubMed ID: 35779234
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria.
Hoppe B; Koch A; Cochat P; Garrelfs SF; Baum MA; Groothoff JW; Lipkin G; Coenen M; Schalk G; Amrite A; McDougall D; Barrios K; Langman CB
Kidney Int; 2022 Mar; 101(3):626-634. PubMed ID: 34481803
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria.
Forbes TA; Brown BD; Lai C
Br J Clin Pharmacol; 2022 Jun; 88(6):2525-2538. PubMed ID: 34022071
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria.
Hoppe B; Groothoff JW; Hulton SA; Cochat P; Niaudet P; Kemper MJ; Deschênes G; Unwin R; Milliner D
Nephrol Dial Transplant; 2011 Nov; 26(11):3609-15. PubMed ID: 21460356
[TBL] [Abstract][Full Text] [Related]
14. Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children.
Sas DJ; Magen D; Hayes W; Shasha-Lavsky H; Michael M; Schulte I; Sellier-Leclerc AL; Lu J; Seddighzadeh A; Habtemariam B; McGregor TL; Fujita KP; Frishberg Y;
Genet Med; 2022 Mar; 24(3):654-662. PubMed ID: 34906487
[TBL] [Abstract][Full Text] [Related]
15. Lumasiran: First Approval.
Scott LJ; Keam SJ
Drugs; 2021 Feb; 81(2):277-282. PubMed ID: 33405070
[TBL] [Abstract][Full Text] [Related]
16. Nephrocalcinosis can disappear in infants receiving early lumasiran therapy.
Kayal D; Sellier-Leclerc AL; Acquaviva-Bourdain C; de Mul A; Cabet S; Bacchetta J
Pediatr Nephrol; 2024 Jul; 39(7):2079-2082. PubMed ID: 38261066
[TBL] [Abstract][Full Text] [Related]
17. New therapeutics for primary hyperoxaluria type 1.
Dejban P; Lieske JC
Curr Opin Nephrol Hypertens; 2022 Jul; 31(4):344-350. PubMed ID: 35266883
[TBL] [Abstract][Full Text] [Related]
18. Is withdrawal of nocturnal hyperhydration possible in children with primary hyperoxaluria treated with RNAi?
Biebuyck N; Destombes C; Prakash R; Boyer O
J Nephrol; 2023 Jun; 36(5):1473-1476. PubMed ID: 37209362
[TBL] [Abstract][Full Text] [Related]
19. Pyridoxamine lowers oxalate excretion and kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria.
Scheinman JI; Voziyan PA; Belmont JM; Chetyrkin SV; Kim D; Hudson BG
Urol Res; 2005 Nov; 33(5):368-71. PubMed ID: 16292584
[TBL] [Abstract][Full Text] [Related]
20. [Bilateral nephrocalcinosis: primary hyperoxaluria involved].
Deprez T; Sempels M
Rev Med Liege; 2022 Jul; 77(7-8):416-420. PubMed ID: 35924494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
